Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Revenue (2016 - 2025)

Historic Revenue for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $32.1 million.

  • ImmunityBio's Revenue rose 42507.37% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.6 million, marking a year-over-year increase of 102595.47%. This contributed to the annual value of $14.7 million for FY2024, which is 227057.88% up from last year.
  • Latest data reveals that ImmunityBio reported Revenue of $32.1 million as of Q3 2025, which was up 42507.37% from $26.4 million recorded in Q2 2025.
  • ImmunityBio's 5-year Revenue high stood at $32.1 million for Q3 2025, and its period low was $14000.0 during Q1 2022.
  • For the 5-year period, ImmunityBio's Revenue averaged around $4.8 million, with its median value being $139000.0 (2021).
  • In the last 5 years, ImmunityBio's Revenue plummeted by 8992.81% in 2022 and then surged by 4119250.0% in 2025.
  • Quarter analysis of 5 years shows ImmunityBio's Revenue stood at $390000.0 in 2021, then tumbled by 81.28% to $73000.0 in 2022, then soared by 90.41% to $139000.0 in 2023, then surged by 5333.09% to $7.6 million in 2024, then skyrocketed by 324.54% to $32.1 million in 2025.
  • Its Revenue stands at $32.1 million for Q3 2025, versus $26.4 million for Q2 2025 and $16.5 million for Q1 2025.